Vanguard Fiduciary Trust
CLRB icon

Vanguard Fiduciary Trust’s Cellectar Biosciences CLRB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Buy
46,220
+29,647
+179% +$82.9K ﹤0.01% 3689
2026
Q1 		$42.1K Buy
+16,573
New +$53.5K ﹤0.01% 3858

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust's CLRB Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Cellectar Biosciences (CLRB) stake by 179% in Q2 2026, buying an estimated $82.9K and bringing the position to 46,220 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #3689.

Vanguard Fiduciary Trust first reported a position in CLRB in Q1 2026 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Vanguard Fiduciary Trust held 46,220 shares of Cellectar Biosciences worth $128K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 29,647 Cellectar Biosciences shares in Q2 2026, an estimated $82.9K.
  • Cellectar Biosciences made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3689 holding.
  • Vanguard Fiduciary Trust first reported a position in Cellectar Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.